VTP Using WST11 in Patients With Untreated Localised Prostate Cancer

• Research type

  Research Study

• Full title

  Vascular Targeted Photodynamic Therapy Using WST11 In Patients With Localised Prostate Cancer - Phase ll, Multicentre, Open-Label Study

• IRAS ID

  25409

• Contact name

  Mark Emberton

• Sponsor organisation

  STEBA BIOTECH S.A.

• Eudract number

  2009-012809-19

• ISRCTN Number

  Unknown

• Research summary

  An investigation of the use of an experimental procedure, which has the potential to be a future treatment for prostate cancer. It is called Vascular Targeted Photodynamic Therapy (VTP). It uses a special drug called WST11, a photosensitiser, which makes the body sensitive to light. This drug is given by infusion into the vein and spreads throughout the body. For the drug to work it needs to be activated by laser light which is given at the same time as the photosensitiser (WST11). Light is directed into the prostate gland through optical fibres, which are put into the prostate through thin needles inserted through the skin between the scrotum and the back passage. The light activates the drug to cause tissue destruction in the prostate. The efficacy of this treatment will be evaluated using a special scan, Magnetic Resonance Imaging (MRI), the PSA (prostate-specific andtigen) level (a blood test that indicates how much cancer there is in your body) and prostate biopsies. Patients asked to participate in this study would have early prostate cancers that are currently not having any active treatment. This new procedure could be an alternative to the current active surveillance approach with fewer complications than after surgery or radiotherapy. VTP can be repeated, if necessary.

• REC name

  South West - Cornwall & Plymouth Research Ethics Committee

• REC reference

  09/H0206/34

• Date of REC Opinion

  5 Aug 2009

• REC opinion

  Further Information Favourable Opinion